sellWeak cluster of 4
Nicole Sweeny sold $20k of KALV
Chief Commercial Officer at KalVista Pharmaceuticals, Inc.. 1,480 shares at an average of $13.42, traded Aug 25, 2025, filed Aug 26, 2025.
Warning score
15Value
$20k
1,480 shares
Holdings after
32,291
-4% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- 0Trade size$20k at market
- 0Share of holdings soldSold 4.4% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-25-023075, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 22, 2025 | MOption exercise Common Stock | +5,000 | - | - | 33,771 | Aug 26, 2025 |
| Aug 25, 2025 | SOpen-market sale Common Stock | -1,480 | $13.42 | $20k | 32,291 | Aug 26, 2025 |
| Aug 22, 2025 | MOption exercise Restricted Stock Unitderivative | -5,000 | $0.00 | $0 | 55,000 | Aug 26, 2025 |
Related signals
Other insiders at KalVista Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 9Weak | KALVsell KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $83k 5,354 shares | -4% | |
| 0Weak | KALVsell KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $17k 1,163 shares | -1% | |
| 35Weak | KalVista Pharmaceuticals, Inc. | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | $120k 7,294 shares | -2% | |
| 22Weak | KalVista Pharmaceuticals, Inc. | Nicole Sweeny Chief Commercial Officer | $51k 3,813 shares | -9% | |
| 23Weak | KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $71k 5,296 shares | -4% | |
| 36Weak | KalVista Pharmaceuticals, Inc. | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | $147k 10,940 shares | -3% | |
| 22Weak | KalVista Pharmaceuticals, Inc. | Christopher Yea CHIEF DEVELOPMENT OFFICER | $58k 4,331 shares | -2% | |
| 39Weak | KalVista Pharmaceuticals, Inc. | Brian Piekos Chief Financial Officer | $60k 4,471 shares | -30% | |
| 21Weak | KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $45k 3,075 shares | -2% | |
| 33Weak | KalVista Pharmaceuticals, Inc. | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | $65k 4,466 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.